| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 23/01/2025 | 00:00 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:TYRA | Tyra Biosciences Inc |
| 22/01/2025 | 14:00 | PR Newswire (US) | Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium | NASDAQ:TYRA | Tyra Biosciences Inc |
| 10/01/2025 | 14:00 | PR Newswire (US) | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/12/2024 | 03:30 | Edgar (US Regulatory) | Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:TYRA | Tyra Biosciences Inc |
| 13/11/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences to Present at Upcoming Investor Conferences | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/11/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/11/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights | NASDAQ:TYRA | Tyra Biosciences Inc |
| 28/10/2024 | 12:00 | PR Newswire (US) | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) | NASDAQ:TYRA | Tyra Biosciences Inc |
| 25/10/2024 | 00:21 | PR Newswire (US) | Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) | NASDAQ:TYRA | Tyra Biosciences Inc |
| 23/10/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET | NASDAQ:TYRA | Tyra Biosciences Inc |
| 23/10/2024 | 02:49 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TYRA | Tyra Biosciences Inc |
| 23/10/2024 | 02:47 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:TYRA | Tyra Biosciences Inc |
| 11/10/2024 | 14:00 | PR Newswire (US) | Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) | NASDAQ:TYRA | Tyra Biosciences Inc |
| 11/09/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference | NASDAQ:TYRA | Tyra Biosciences Inc |
| 10/09/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/08/2024 | 22:10 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/08/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights | NASDAQ:TYRA | Tyra Biosciences Inc |
| 02/07/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) | NASDAQ:TYRA | Tyra Biosciences Inc |
| 09/05/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/05/2024 | 22:34 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/05/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors | NASDAQ:TYRA | Tyra Biosciences Inc |
| 19/03/2024 | 21:05 | PR Newswire (US) | Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights | NASDAQ:TYRA | Tyra Biosciences Inc |
| 13/02/2024 | 22:36 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/02/2024 | 22:05 | PR Newswire (US) | Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference | NASDAQ:TYRA | Tyra Biosciences Inc |
| 02/02/2024 | 14:00 | PR Newswire (US) | Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing | NASDAQ:TYRA | Tyra Biosciences Inc |
| 01/02/2024 | 23:30 | PR Newswire (US) | Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia | NASDAQ:TYRA | Tyra Biosciences Inc |
| 22/12/2023 | 15:00 | PR Newswire (US) | Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 | NASDAQ:TYRA | Tyra Biosciences Inc |
| 08/11/2023 | 22:05 | PR Newswire (US) | Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference | NASDAQ:TYRA | Tyra Biosciences Inc |
| 07/11/2023 | 22:05 | PR Newswire (US) | Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights | NASDAQ:TYRA | Tyra Biosciences Inc |
| 21/09/2023 | 14:00 | PR Newswire (US) | Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings | NASDAQ:TYRA | Tyra Biosciences Inc |